A Phase 2, Multi-Cohort, Open-Label Study of Intratumoral Tavokinogene Telseplasmid Plus Electroporation in Combination With Intravenous Pembrolizumab Therapy With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 05 Jun 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Tavokinogene telseplasmid (Primary) ; Antineoplastics; Paclitaxel
Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
Focus Registrational; Therapeutic Use
Acronyms KEYNOTE-890
Sponsors OncoSec Medical

Most Recent Events

30 May 2023 Planned End Date changed from 1 Aug 2024 to 1 Sep 2024.
30 May 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Apr 2024.
30 May 2023 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight